Skip to Content

Imfinzi

In the US, Imfinzi (durvalumab systemic) is a member of the drug class anti-PD-1 monoclonal antibodies and is used to treat Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Urothelial Carcinoma.

US matches:

Ingredient matches for Imfinzi

Durvalumab

Durvalumab is reported as an ingredient of Imfinzi in the following countries:

  • United States

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.